SCHEDULE: Alpha Capital Anstalt Updates Qualigen Therapeutics Stake

Alpha Capital Anstalt has updated its beneficial ownership in Qualigen Therapeutics, Inc., reporting a 2.223% stake.

Summary

• Alpha Capital Anstalt holds 36,434 shares of Qualigen Therapeutics, Inc. common stock.
• This represents 2.223% of the company's outstanding shares.
• The percentage is based on 1,635,475 shares outstanding as of July 18, 2025, as reported in Qualigen's Form 10-Q filed with the SEC on July 21, 2025.
• Alpha Capital Anstalt, a Liechtenstein-based entity, has sole voting and dispositive power over all 36,434 shares.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: A standard beneficial ownership filing, indicating a passive stake below the 5% threshold for new 13G filings, but an amendment to a previous filing. It provides no new fundamental information about the company's operations or financial performance.

Positives

• A passive investor, Alpha Capital Anstalt, continues to hold a stake in the company, indicating ongoing interest.

Negatives

• The reported stake of 2.223% is below the 5% threshold, suggesting a potential reduction in holding or a routine update for a stake that has fallen below the initial filing threshold.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this beneficial ownership filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Qualigen Therapeutics, Inc.'s future operations or financial performance.

Industry Context

This Schedule 13G filing is a routine disclosure of an investor's stake and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Provides transparency regarding a passive institutional investor's current stake, which is below the 5% threshold.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of a passive ownership stake by Alpha Capital Anstalt in Qualigen Therapeutics, Inc. The reported stake of 2.223% is below the 5% threshold that typically triggers initial Schedule 13G filings for passive investors, suggesting this is an amendment to a previously larger or different stake. The filing explicitly states the shares are not held for control purposes. As such, it provides no new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment thesis. The current holding indicates continued, albeit passive, interest from Alpha Capital Anstalt. Investors should continue to monitor Qualigen's operational and financial reports for actionable insights.

Keywords

Qualigen Therapeutics, Alpha Capital Anstalt, Beneficial Ownership, Schedule 13G, Common Stock, QLGN